Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Neoplasm
Explore 890 assets in Neoplasm →Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
Mohammed Milhem
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07404332CT.gov 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors | — | Recruiting | — | — | — |
NCT06651593CT.gov Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors | — | Recruiting | — | — | — |
NCT06384807CT.gov A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06171750CT.gov Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06090266CT.gov A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | — | Recruiting | — | — | — |
NCT06022029CT.gov A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | — | Recruiting | — | — | — |
NCT05878288CT.gov Deep sequencIng in Cutaneous Squamous CEll caRciNomas | — | Active Not Recruiting | — | — | — |
NCT05259696CT.gov Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) | — | Completed | — | — | — |
NCT05094804CT.gov A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer (this asset) | Mohammed Milhem | P2 | CCC · 54 |
| Panitumumab | Astellas Pharma Inc | P2 | BBB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Relatlimab | Bristol-Myers Squibb | P2 | BB |
| Vitamin D | Tanta University | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Skin Squamous Cell Carcinoma | — | P3 | BB · 66 |
| Lung Cancer | — | P2/3 | BB · 65 |
| Nonpapillary Renal Cell Carcinoma | — | P2 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g4-anti-human-programmed-cell-death-protein-1-human-monoclonal-regn2810-heavy-chain-disulfide-with-human-monoclonal-regn2810-kappa-chain-dimer-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →